BIOGENBIOGENBIOGEN

BIOGEN

No trades
See on Supercharts
Next report date
Report period
Q2 2024
EPS estimate
3.71EUR
Revenue estimate
‪2.22 B‬EUR
Market capitalization
‪28.35 B‬EUR
‪1.05 B‬EUR
‪8.53 B‬EUR
‪144.43 M‬
Beta (1Y)
0.82

About Biogen Inc.

CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Employees (FY)
‪7.57 K‬
Founded
1978
FIGI
BBG01K3X4XJ1
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where 1BIIB is featured.

Frequently Asked Questions

The current price of 1BIIB is 195.90 EUR — it has increased by 1.06% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange BIOGEN stocks are traded under the ticker 1BIIB.
BIOGEN is going to release the next earnings report on Jul 23, 2024. Keep track of upcoming events with our Earnings Calendar.
1BIIB stock is 1.38% volatile and has beta coefficient of 0.82. Check out the list of the most volatile stocks — is BIOGEN there?
1BIIB earnings for the last quarter are 2.67 EUR per share, whereas the estimation was 2.88 EUR resulting in a −7.35% surprise. The estimated earnings for the next quarter are 3.22 EUR per share. See more details about BIOGEN earnings.
BIOGEN revenue for the last quarter amounts to ‪2.16 B‬ EUR despite the estimated figure of ‪2.23 B‬ EUR. In the next quarter revenue is expected to reach ‪2.14 B‬ EUR.
Yes, you can track BIOGEN financials in yearly and quarterly reports right on TradingView.
1BIIB stock has risen by 6.93% compared to the previous week, the month change is a 1.76% fall, over the last year BIOGEN has showed a 6.71% decrease.
1BIIB net income for the last quarter is ‪364.60 M‬ EUR, while the quarter before that showed ‪226.23 M‬ EUR of net income which accounts for 61.16% change. Track more BIOGEN financial stats to get the full picture.
Today BIOGEN has the market capitalization of ‪28.45 B‬, it has decreased by 0.84% over the last week.
No, 1BIIB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 1BIIB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN stock right from TradingView charts — choose your broker and connect to your account.
1BIIB reached its all-time high on Jan 9, 2024 with the price of 244.60 EUR, and its all-time low was 177.65 EUR and was reached on Apr 19, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 29, 2024, the company has ‪7.57 K‬ employees. See our rating of the largest employees — is BIOGEN on this list?
We've gathered analysts' opinions on BIOGEN future price: according to them, 1BIIB price has a max estimate of 327.34 EUR and a min estimate of 187.05 EUR. Read a more detailed BIOGEN forecast: see what analysts think of BIOGEN and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN EBITDA is ‪2.10 B‬ EUR, and current EBITDA margin is 22.58%. See more stats in BIOGEN financial statements.